Campillo N E, Páez J A
Instituto de Q. Médica (CSIC). Juan de la Cierva, 3, 28006-Madrid, Spain.
Mini Rev Med Chem. 2009 May;9(5):539-59. doi: 10.2174/138955709788167628.
Alzheimer's disease is a chronic and progressive neurodegenerative disorder. The presence of functional cannabinoid CB2 receptors in central nervous system (CNS) has provoked that this receptor and its agonist ligands are now considered as promising pharmacological targets for neurological diseases. Herein, we review the evidences supporting the potential role of the ECS as a therapeutic target, focused on CB2 receptor and its ligands, for the treatment of Alzheimer's disease.
阿尔茨海默病是一种慢性进行性神经退行性疾病。中枢神经系统（CNS）中功能性大麻素CB2受体的存在促使该受体及其激动剂配体如今被视为神经疾病有前景的药理学靶点。在此，我们综述支持内源性大麻素系统（ECS）作为治疗靶点（聚焦于CB2受体及其配体）治疗阿尔茨海默病潜在作用的证据。
